Clinical Trials Sponsored by Alexis Roth

Total 830 results

Alexis Roth
University of Miami; Beth Israel Deaconess Medical Center; University of Michigan and other collaborators

Recruiting

Optimizing CAB-LA as PrEP for Women Who Inject Drugs

HIV Infections | Opioid Use | Trauma, Psychological

United States
Aleris Eye

Recruiting

Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods

Cataract

Sweden
Aleris Hospital

Active, not recruiting

Non-randomized Prospective Comparison Between SASI Bipartition and RYGB

Postoperative Complications | Metabolic Syndrome | Obesity, Morbid | Bariatric Surgery Candidate

Norway
Alexis FERRE

Recruiting

Patients With Severe Acute Exacerbation of COPD Ans Admitted in ICU Register. (COPDregister)

COPD Exacerbation

France
Aleris Obesity

Completed

Effects of Long Biliopancreatic Limb vs. Long Alimentary Limb in Superobesity, a Randomized Study

Weight Loss | Morbid Obesity

Sweden
Aleris Helse

Completed

Perioperative Hypothermia Hypothermia in Ambulatory Surgery

Perioperative/Postoperative Complications

Norway
John Roth

Completed

Feasibility Study of The Use of FLEX HD® Surgical Implant or STRATTICE® Reconstructive Tissue Matrix in The Closure of Abdominal Wall Defects With Component Separation in Clean or Contaminated Cases (Flex HD)

Hernia Repair With Compartment Syndrome

United States
John Roth

Completed

A Prospective, Observational Study Utilizing Phasix™ Mesh During Ventral and Incisional Hernia Repair Surgery

Ventral Hernia

United States
Aleris Helse
Novartis

Completed

A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO

Central Retinal Vein Occlusion | Macular Edema

Norway
Alexion

Recruiting

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (SANCTUARY)

Lupus Nephritis | Immunoglobulin A Nephropathy

United States, Australia, Canada, France, Germany, Italy, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Sweden, Taiwan, United Kingdom
Alexion

Recruiting

Lysosomal Acid Lipase (LAL) Deficiency Registry (ALX-LALD-501)

Wolman Disease | Cholesterol Ester Storage Disease | Lysosomal Acid Lipase Deficiency | Acid Cholesteryl Ester Hydrolase Deficiency, Type 2 | Acid Lipase Deficiency | LIPA Deficiency | LAL-Deficiency

France, Belgium, United States, Spain, Germany, Greece, Israel, Italy, Slovenia, United Kingdom, Brazil, Canada, Denmark, Australia, Croatia, Czechia, Ireland, Mexico, Netherlands, Poland, Portugal, Saudi Arabia
Alexion

Terminated

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative Glomerulonephritis

United States, Australia, Belgium, Italy, Netherlands
Alexion

Completed

Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

Wilson Disease

United States
Alexion

Completed

A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

United States, France, Germany, Spain, Switzerland, Netherlands, Canada, Austria
Alexion

Completed

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

Proteinuria

Korea, Republic of
Alexion

Completed

A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants

Healthy

United Kingdom
Alexion

Completed

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Korea, Republic of, Canada, France, Germany, Spain, United Kingdom, Japan, Australia, Italy, Netherlands
Alexion

Terminated

Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery (Annexa-S)

Surgery

United States, Germany, Israel, France, Austria, Japan
Alexion

Completed

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

Healthy

United Kingdom
Alexion

Completed

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

Healthy

United States
Alexion

Completed

A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype

Wolman Disease | Lysosomal Acid Lipase Deficiency

United States, Canada, United Kingdom, Italy, France
Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
Alexion

Recruiting

US Selumetinib Registry

Neurofibromatosis Type 1 | Plexiform Neurofibromas

United States
Alexion

Recruiting

Study of ALXN2050 in Participants With Hepatic Impairment

Healthy | Impaired Hepatic Function

United States
Alexion

Recruiting

A Prospective Sub-Study of the Global Hypophosphatasia Registry

Hypophosphatasia

United States
Alexion

Terminated

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

Wilson Disease

United States, France, Germany, Spain, Canada, Singapore, Poland, Denmark, Hungary, Australia, Austria, Czechia, Hong Kong, Israel, Japan, Korea, Republic of, New Zealand, Russian Federation, Serbia, Taiwan, Turkey, United Kingdom
Alexion

Active, not recruiting

Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease (PHOENIX)

Sickle Cell Disease (SCD)

United States, France
Alexion

Active, not recruiting

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

United States, Australia, Austria, Canada, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Spain, United Kingdom
Alexion

Completed

A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults

Healthy

United States
Alexion

Completed

A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants

Healthy

United Kingdom
Alexion

Completed

A Study of a Single Dose of ALXN1210 in Healthy Participants

Healthy

Canada
Alexion

Completed

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Healthy Participants

United States
Alexion

Completed

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

Healthy

United States
Alexion

Withdrawn

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

United States
Alexion

Completed

The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment

Wilson Disease

United States, Germany, Austria, Poland, United Kingdom
Alexion

Terminated

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.

HIV Infections

United States
Alexion

Completed

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS (aHUS)

Atypical Hemolytic Uremic Syndrome

Canada, United Kingdom, France, Germany, Netherlands, Sweden, Italy
Alexion

Completed

Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes (EXPLORE)

Hemoglobinuria
Alexion

Completed

Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

Wilson Disease

United States, New Zealand, United Kingdom
Alexion

Completed

Study of ALXN2050 in Participants With Renal Impairment

Healthy | Renal Impairment

United States
Alexion

Completed

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

Wilson Disease

United States
Alexion

Withdrawn

Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)

Hypophosphatasia
Alexion

Completed

Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults

Healthy

United Kingdom
Alexion

Completed

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

Healthy

United States
Alexion

No longer available

Early Access Program for ALXN1840 in Patients With Wilson Disease

Wilson Disease
Alexion

Active, not recruiting

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
Alexion

Completed

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

France, United Kingdom, Norway, Russian Federation, Netherlands, United States
Alexion

Completed

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Atypical Hemolytic-Uremic Syndrome

United Kingdom, United States, France, Italy, Germany, Spain, Belgium
Alexion

Approved for marketing

The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol (EMBRACE)

Hemoglobinuria, Paroxysmal

United States
Alexion

Terminated

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.

Chronic Hepatitis B

Clinical Trials Sponsored by Alexis Roth

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations